<ul>
<li><strong>預計下週將為首位患者進行鼻用 Foralumab 給藥</strong></li>
<li><strong>PET 掃描顯示接受 Leqembi®（Lecanemab）抗澱粉樣蛋白治療的阿爾茨海默病患者存在未治療的神經炎症</strong></li>
</ul>
<p>波士頓，2025 年 12 月 12 日（全球新聞稿）——Tiziana Life Sciences, Ltd.（納斯達克：TLSA）（“Tiziana” 或 “公司”），一家開發突破性免疫調節療法的生物技術公司，其主要開發候選藥物為鼻用 foralumab，這是一種完全人源的抗 CD3 單克隆抗體，宣佈其第二階段隨機、安慰劑對照的早期阿爾茨海默病臨牀試驗已開始招募，並計劃下週為首位患者給藥。</p>
<p>第二階段臨牀試驗將評估鼻用 foralumab 作為單藥治療和與 FDA 批准的抗澱粉樣蛋白治療藥物 lecanemab 或 donanemab 聯合使用在早期阿爾茨海默病（AD）患者中的效果。試驗中首批篩選參與者的基線臨牀評估、認知測試、TSPO-PET 成像和液體生物標誌物已完成。</p>
<p>臨牀試驗的啓動得到了新的 TSPO-PET 成像證據的支持，該證據表明儘管接受了 lecanemab 治療，但阿爾茨海默病患者的微膠質細胞仍持續廣泛激活，確認神經炎症在澱粉樣斑塊減少後仍然存在。Lecanemab 由 Eisai 和 Biogen 以 Leqembi®的名義上市，是 FDA 批准的兩種用於治療早期阿爾茨海默病的抗澱粉樣蛋白療法之一，已證明能夠減少β-澱粉樣蛋白斑塊。</p>
<p><strong>圖 1.</strong> 使用 lecanemab 治療的阿爾茨海默病患者的 TSPO-PET 掃描，顯示大腦中微膠質細胞持續廣泛激活。</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/48f529f2-1fc4-4466-ae1d-84fa808979a8/image2.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/48f529f2-1fc4-4466-ae1d-84fa808979a8/image2.png"/></p>
<p>Tiziana 科學顧問委員會主席、布萊根婦女醫院神經疾病安·羅姆尼中心的共同主任 Howard Weiner 博士表示：“這一 PET 發現是一個關鍵的見解：清除澱粉樣蛋白並不會關閉大腦的炎症反應。我們相信鼻用 foralumab 直接針對這種殘餘的神經炎症，通過誘導調節性 T 細胞遷移到大腦並平息激活的微膠質細胞——這一機制我們已經證明能夠減少繼發性進展性多發性硬化症中的微膠質細胞激活。”</p>
<p><strong>圖 2.</strong> 鼻用 foralumab 治療的多發性硬化症患者的 TSPO-PET 掃描，顯示在 6 個月的治療期間微膠質細胞激活顯著減少。</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/bc4d6ed6-2598-489a-859a-f4387ad81ba0/image3.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/bc4d6ed6-2598-489a-859a-f4387ad81ba0/image3.png"/></p>
<p><strong>第二階段試驗設計與理由</strong></p>
<p>該研究將評估鼻用 foralumab 是否：</p>
<ul>
<li>作為單藥治療，減少微膠質細胞激活並通過抑制神經炎症減緩認知衰退。</li>
<li>與 lecanemab 或 donanemab 聯合使用時，是否通過同時針對澱粉樣病理和持續的微膠質細胞炎症提供附加或協同效益。</li>
</ul>
<p>“隨着招募工作的展開，基線神經影像學和生物標誌物的獲取，我們即將測試一種根本新的阿爾茨海默病治療方法——一種治療與持續神經退行性變相關的慢性腦炎症的方法。我們預計首位患者將在幾天內開始給藥，” Tiziana Life Sciences 首席執行官 Ivor Elrifi 表示。“這一里程碑標誌着測試免疫調節單獨或與澱粉樣去除結合是否能夠實現疾病修飾的重要一步。無論是否接受抗澱粉樣蛋白治療，阿爾茨海默病中的炎症 PET 證據為這一創新策略提供了明確的生物學依據。”</p>
<p>鼻用 foralumab 是一種完全人源的抗 CD3 單克隆抗體，旨在誘導調節性 T 細胞並抑制病理性神經炎症，使其成為解決阿爾茨海默病中即使在澱粉樣清除後仍然活躍的炎症成分的潛在首創療法。</p>
<p><strong>關於第二階段試驗</strong></p>
<p>第二階段研究旨在評估鼻用 foralumab 作為單藥治療和與 lecanemab 或 donanemab 聯合使用在早期/輕度阿爾茨海默病中的安全性、耐受性和有效性。關鍵終點將包括神經炎症的測量（通過 TSPO-PET 成像）、認知功能和與澱粉樣蛋白和 tau 病理相關的生物標誌物變化。該試驗的結果將為未來的發展提供信息，並可能建立一種新的治療阿爾茨海默病的範式，單獨針對神經炎症或與抗澱粉樣蛋白治療結合使用。</p>
<p><strong>關於 Foralumab</strong></p>
<p>Foralumab 是一種完全人源的抗 CD3 單克隆抗體，是一種生物藥物候選者，已顯示在鼻用給藥時刺激 T 調節細胞。目前，已有 14 名非活動性繼發性進展性多發性硬化症（na-SPMS）患者在開放標籤的中型擴展使用（EA）項目（NCT06802328）中接受了給藥，所有患者在 6 個月內均出現了疾病改善或穩定。此外，鼻用 foralumab 目前正在一項針對非活動性繼發性進展性多發性硬化症患者的第二階段隨機、雙盲、安慰劑對照、多中心劑量範圍試驗中進行研究（NCT06292923）。</p>
<p>Foralumab 是目前唯一在臨牀開發中的完全人源抗 CD3 單克隆抗體（mAb）。鼻用 foralumab 的免疫調節代表了治療神經炎症和神經退行性人類疾病的新途徑。[1],[2]</p>
<p><strong>關於 Tiziana Life Sciences</strong></p>
<p>Tiziana Life Sciences 是一家臨牀階段的生物製藥公司，開發突破性療法，利用變革性的藥物遞送技術實現替代免疫療法。Tiziana 創新的鼻用給藥方法有潛力在療效、安全性和耐受性方面提供比靜脈（IV）給藥更好的改善。Tiziana 的主要候選藥物鼻用 foralumab 是目前唯一在臨牀開發中的全人源抗 CD3 單克隆抗體，已在研究中顯示出良好的安全性和臨牀反應。Tiziana 的替代免疫療法技術已獲得專利，多個申請正在等待中，預計將允許廣泛的管線應用。</p>
<p>有關 Tiziana Life Sciences 及其創新療法管線的更多信息，請訪問 www.tizianalifesciences.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本公告中所作的某些聲明為前瞻性聲明。這些前瞻性聲明不是歷史事實，而是基於公司當前的期望、估計和對其行業的預測、信念和假設。諸如 “預期”、“期望”、“打算”、“計劃”、“相信”、“尋求”、“估計” 等詞語旨在識別前瞻性聲明。這些聲明並不保證未來的表現，並且受到已知和未知的風險、不確定性和其他因素的影響，其中一些超出了公司的控制範圍，難以預測，可能導致實際結果與前瞻性聲明中表達或預測的結果有重大差異。公司提醒證券持有者和潛在證券持有者不要對這些前瞻性聲明過於依賴，這些聲明僅反映公司在本公告日期的觀點。實際結果可能因各種重要因素而與這些前瞻性聲明所指示的結果有重大差異，包括：與市場條件相關的不確定性以及在 Tiziana 截至 2024 年 12 月 31 日的 20-F 表年度報告中更全面描述的其他因素，以及向證券交易委員會提交的其他定期報告。本公告中所作的前瞻性聲明僅與聲明作出之日的事件相關。除法律或任何適當監管機構要求外，公司不承擔公開發布任何修訂或更新這些前瞻性聲明以反映公告日期後發生的事件、情況或意外事件的義務。</p>
<p><strong>如需進一步諮詢：</strong></p>
<p><strong>Tiziana Life Sciences Ltd</strong></p>
<p>Paul Spencer，業務發展與投資者關係</p>
<p>+44 (0) 207 495 2379</p>
<p>電子郵件：info@tizianalifesciences.com</p>
<p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
<p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
<p>本公告附帶的照片可在以下網址獲取</p>
<p>https://www.globenewswire.com/NewsRoom/AttachmentNg/48f529f2-1fc4-4466-ae1d-84fa808979a8</p>
<p>https://www.globenewswire.com/NewsRoom/AttachmentNg/bc4d6ed6-2598-489a-859a-f4387ad81ba0</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UTTJNQ00zTXpFNU16TTVJekl4TWpNNE9EVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UTTJNQ00zTXpFNU16TTVJekl4TWpNNE9EVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTc0Yzc3OGEtNzc3OC00OGU1LTkyNjQtNmRhN2FhNjMyM2M4LTExMzU0NTYtMjAyNS0xMi0xMi1lbg==/tiny/Tiziana-Life-Sciences-Plc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTc0Yzc3OGEtNzc3OC00OGU1LTkyNjQtNmRhN2FhNjMyM2M4LTExMzU0NTYtMjAyNS0xMi0xMi1lbg==/tiny/Tiziana-Life-Sciences-Plc.png"/></p>

TLSA

<p>Tiziana Life Sciences 計劃在下週為其第二階段阿爾茨海默病試驗的首位患者給藥。該試驗將評估鼻用 foralumab，既作為單藥治療，也與抗澱粉樣蛋白療法 lecanemab 或 donanemab 聯合使用。該研究旨在解決阿爾茨海默病患者的神經炎症問題，可能提供一種新的治療範式。基線評估和影像學檢查已完成，試驗將重點關注安全性、有效性和認知功能的改善</p>

<ul>
<li><strong>First Patient Expected to be Dosed Next Week with Intranasal Foralumab</strong></li>
<li><strong>PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi</strong> <strong>®</strong> <strong>(Lecanemab) Anti-Amyloid Therapy</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>預計下週將為首位患者進行鼻用 Foralumab 給藥</strong></li>
<li><strong>PET 掃描顯示接受 Leqembi®（Lecanemab）抗澱粉樣蛋白治療的阿爾茨海默病患者存在未治療的神經炎症</strong></li>
</ul>
</div><p>BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that enrolment has begun in its Phase 2 randomized, placebo-controlled early Alzheimer’s clinical trial and plans to dose the first patient next week.</p>
<div class="lb-trans"><p>波士頓，2025 年 12 月 12 日（全球新聞稿）——Tiziana Life Sciences, Ltd.（納斯達克：TLSA）（“Tiziana” 或 “公司”），一家開發突破性免疫調節療法的生物技術公司，其主要開發候選藥物為鼻用 foralumab，這是一種完全人源的抗 CD3 單克隆抗體，宣佈其第二階段隨機、安慰劑對照的早期阿爾茨海默病臨牀試驗已開始招募，並計劃下週為首位患者給藥。</p>
</div><p>The Phase 2 clinical trial will evaluate intranasal foralumab both as monotherapy and in combination with an FDA approved anti-amyloid therapy, lecanemab or donanemab, in patients with early Alzheimer’s disease (AD). Baseline clinical assessments, cognitive testing, TSPO-PET imaging, and fluid biomarkers have been completed in the first participants screened in the trial.</p>
<div class="lb-trans"><p>第二階段臨牀試驗將評估鼻用 foralumab 作為單藥治療和與 FDA 批准的抗澱粉樣蛋白治療藥物 lecanemab 或 donanemab 聯合使用在早期阿爾茨海默病（AD）患者中的效果。試驗中首批篩選參與者的基線臨牀評估、認知測試、TSPO-PET 成像和液體生物標誌物已完成。</p>
</div><p>The clinical trial launch is supported by new TSPO-PET imaging evidence demonstrating persistent and widespread microglial activation in an Alzheimer’s patient despite treatment with lecanemab, confirming that neuroinflammation remains present even after amyloid plaque reduction. Lecanemab, marketed by Eisai and Biogen as Leqembi®, is one of the two FDA-approved anti-amyloid therapies for treating early Alzheimer’s and is proven to reduce beta-amyloid plaques.</p>
<div class="lb-trans"><p>臨牀試驗的啓動得到了新的 TSPO-PET 成像證據的支持，該證據表明儘管接受了 lecanemab 治療，但阿爾茨海默病患者的微膠質細胞仍持續廣泛激活，確認神經炎症在澱粉樣斑塊減少後仍然存在。Lecanemab 由 Eisai 和 Biogen 以 Leqembi®的名義上市，是 FDA 批准的兩種用於治療早期阿爾茨海默病的抗澱粉樣蛋白療法之一，已證明能夠減少β-澱粉樣蛋白斑塊。</p>
</div><p><strong>Figure 1.</strong> TSPO-PET scan of an Alzheimer’s patient treated with lecanemab demonstrating persistent and widespread microglial activation throughout the brain.</p>
<div class="lb-trans"><p><strong>圖 1.</strong> 使用 lecanemab 治療的阿爾茨海默病患者的 TSPO-PET 掃描，顯示大腦中微膠質細胞持續廣泛激活。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/48f529f2-1fc4-4466-ae1d-84fa808979a8/image2.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/48f529f2-1fc4-4466-ae1d-84fa808979a8/image2.png"/></p>
<p>Dr. Howard Weiner, Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham, stated, “This PET finding is a critical insight: clearing amyloid does not turn off the brain’s inflammatory response. We believe intranasal foralumab directly addresses this residual neuroinflammation by inducing regulatory T cells to migrate to the brain and calm activated microglia — a mechanism we have already shown reduces microglial activation in secondary progressive multiple sclerosis.”</p>
<div class="lb-trans"><p>Tiziana 科學顧問委員會主席、布萊根婦女醫院神經疾病安·羅姆尼中心的共同主任 Howard Weiner 博士表示：“這一 PET 發現是一個關鍵的見解：清除澱粉樣蛋白並不會關閉大腦的炎症反應。我們相信鼻用 foralumab 直接針對這種殘餘的神經炎症，通過誘導調節性 T 細胞遷移到大腦並平息激活的微膠質細胞——這一機制我們已經證明能夠減少繼發性進展性多發性硬化症中的微膠質細胞激活。”</p>
</div><p><strong>Figure 2.</strong> TSPO-PET scans from intranasal foralumab-treated MS patients showing marked reduction in microglial activation over a 6-month treatment period.</p>
<div class="lb-trans"><p><strong>圖 2.</strong> 鼻用 foralumab 治療的多發性硬化症患者的 TSPO-PET 掃描，顯示在 6 個月的治療期間微膠質細胞激活顯著減少。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/bc4d6ed6-2598-489a-859a-f4387ad81ba0/image3.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/bc4d6ed6-2598-489a-859a-f4387ad81ba0/image3.png"/></p>
<p><strong>Phase 2 Trial Design and Rationale</strong></p>
<div class="lb-trans"><p><strong>第二階段試驗設計與理由</strong></p>
</div><p>The study will evaluate whether intranasal foralumab:</p>
<div class="lb-trans"><p>該研究將評估鼻用 foralumab 是否：</p>
</div><ul>
<li>As a monotherapy, reduces microglial activation and slows cognitive decline by suppressing neuroinflammation.</li>
<li>In combination with lecanemab or donanemab will provide additive or synergistic benefit by simultaneously targeting amyloid pathology and persistent microglial inflammation.</li>
</ul>
<div class="lb-trans"><ul>
<li>作為單藥治療，減少微膠質細胞激活並通過抑制神經炎症減緩認知衰退。</li>
<li>與 lecanemab 或 donanemab 聯合使用時，是否通過同時針對澱粉樣病理和持續的微膠質細胞炎症提供附加或協同效益。</li>
</ul>
</div><p>“With enrolment now underway and baseline neuroimaging and biomarkers secured, we are on the verge of testing a fundamentally new approach to Alzheimer’s — one that treats the chronic brain inflammation that is associated with ongoing neurodegeneration. We expect the first patients to begin dosing within days,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “This milestone marks an important step toward testing whether immune modulation alone, or in combination with amyloid removal, can achieve disease modification. The PET evidence of inflammation in AD with or without anti-amyloid treatment provides a clear biological rationale for this innovative strategy.”</p>
<div class="lb-trans"><p>“隨着招募工作的展開，基線神經影像學和生物標誌物的獲取，我們即將測試一種根本新的阿爾茨海默病治療方法——一種治療與持續神經退行性變相關的慢性腦炎症的方法。我們預計首位患者將在幾天內開始給藥，” Tiziana Life Sciences 首席執行官 Ivor Elrifi 表示。“這一里程碑標誌着測試免疫調節單獨或與澱粉樣去除結合是否能夠實現疾病修飾的重要一步。無論是否接受抗澱粉樣蛋白治療，阿爾茨海默病中的炎症 PET 證據為這一創新策略提供了明確的生物學依據。”</p>
</div><p>Intranasal foralumab is a fully human anti-CD3 monoclonal antibody designed to induce Tregs and suppress pathological neuroinflammation, positioning it as a potential first-in-class therapy to address the inflammatory component of Alzheimer’s disease that remains active even after amyloid clearance.</p>
<div class="lb-trans"><p>鼻用 foralumab 是一種完全人源的抗 CD3 單克隆抗體，旨在誘導調節性 T 細胞並抑制病理性神經炎症，使其成為解決阿爾茨海默病中即使在澱粉樣清除後仍然活躍的炎症成分的潛在首創療法。</p>
</div><p><strong>About the Phase 2 Trial</strong></p>
<div class="lb-trans"><p><strong>關於第二階段試驗</strong></p>
</div><p>The Phase 2 study is designed to evaluate the safety, tolerability, and efficacy of intranasal foralumab as both a monotherapy and in combination with lecanemab or donanemab in early/mild AD. Key endpoints will include measures of neuroinflammation (via TSPO-PET imaging), cognitive function, and biomarker changes related to amyloid and tau pathology. Results from this trial will inform future development and may establish a new paradigm for treating AD by targeting neuroinflammation alone or in combination with anti-amyloid therapy.</p>
<div class="lb-trans"><p>第二階段研究旨在評估鼻用 foralumab 作為單藥治療和與 lecanemab 或 donanemab 聯合使用在早期/輕度阿爾茨海默病中的安全性、耐受性和有效性。關鍵終點將包括神經炎症的測量（通過 TSPO-PET 成像）、認知功能和與澱粉樣蛋白和 tau 病理相關的生物標誌物變化。該試驗的結果將為未來的發展提供信息，並可能建立一種新的治療阿爾茨海默病的範式，單獨針對神經炎症或與抗澱粉樣蛋白治療結合使用。</p>
</div><p><strong>About Foralumab</strong></p>
<div class="lb-trans"><p><strong>關於 Foralumab</strong></p>
</div><p>Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).</p>
<div class="lb-trans"><p>Foralumab 是一種完全人源的抗 CD3 單克隆抗體，是一種生物藥物候選者，已顯示在鼻用給藥時刺激 T 調節細胞。目前，已有 14 名非活動性繼發性進展性多發性硬化症（na-SPMS）患者在開放標籤的中型擴展使用（EA）項目（NCT06802328）中接受了給藥，所有患者在 6 個月內均出現了疾病改善或穩定。此外，鼻用 foralumab 目前正在一項針對非活動性繼發性進展性多發性硬化症患者的第二階段隨機、雙盲、安慰劑對照、多中心劑量範圍試驗中進行研究（NCT06292923）。</p>
</div><p>Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]</p>
<div class="lb-trans"><p>Foralumab 是目前唯一在臨牀開發中的完全人源抗 CD3 單克隆抗體（mAb）。鼻用 foralumab 的免疫調節代表了治療神經炎症和神經退行性人類疾病的新途徑。[1],[2]</p>
</div><p><strong>About Tiziana Life Sciences</strong></p>
<div class="lb-trans"><p><strong>關於 Tiziana Life Sciences</strong></p>
</div><p>Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.</p>
<div class="lb-trans"><p>Tiziana Life Sciences 是一家臨牀階段的生物製藥公司，開發突破性療法，利用變革性的藥物遞送技術實現替代免疫療法。Tiziana 創新的鼻用給藥方法有潛力在療效、安全性和耐受性方面提供比靜脈（IV）給藥更好的改善。Tiziana 的主要候選藥物鼻用 foralumab 是目前唯一在臨牀開發中的全人源抗 CD3 單克隆抗體，已在研究中顯示出良好的安全性和臨牀反應。Tiziana 的替代免疫療法技術已獲得專利，多個申請正在等待中，預計將允許廣泛的管線應用。</p>
</div><p>For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.</p>
<div class="lb-trans"><p>有關 Tiziana Life Sciences 及其創新療法管線的更多信息，請訪問 www.tizianalifesciences.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Tiziana’s Annual Report on Form 20-F for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.</p>
<div class="lb-trans"><p>本公告中所作的某些聲明為前瞻性聲明。這些前瞻性聲明不是歷史事實，而是基於公司當前的期望、估計和對其行業的預測、信念和假設。諸如 “預期”、“期望”、“打算”、“計劃”、“相信”、“尋求”、“估計” 等詞語旨在識別前瞻性聲明。這些聲明並不保證未來的表現，並且受到已知和未知的風險、不確定性和其他因素的影響，其中一些超出了公司的控制範圍，難以預測，可能導致實際結果與前瞻性聲明中表達或預測的結果有重大差異。公司提醒證券持有者和潛在證券持有者不要對這些前瞻性聲明過於依賴，這些聲明僅反映公司在本公告日期的觀點。實際結果可能因各種重要因素而與這些前瞻性聲明所指示的結果有重大差異，包括：與市場條件相關的不確定性以及在 Tiziana 截至 2024 年 12 月 31 日的 20-F 表年度報告中更全面描述的其他因素，以及向證券交易委員會提交的其他定期報告。本公告中所作的前瞻性聲明僅與聲明作出之日的事件相關。除法律或任何適當監管機構要求外，公司不承擔公開發布任何修訂或更新這些前瞻性聲明以反映公告日期後發生的事件、情況或意外事件的義務。</p>
</div><p><strong>For further inquiries:</strong></p>
<div class="lb-trans"><p><strong>如需進一步諮詢：</strong></p>
</div><p><strong>Tiziana Life Sciences Ltd</strong></p>
<div class="lb-trans"><p><strong>Tiziana Life Sciences Ltd</strong></p>
</div><p>Paul Spencer, Business Development, and Investor Relations</p>
<div class="lb-trans"><p>Paul Spencer，業務發展與投資者關係</p>
</div><p>+44 (0) 207 495 2379</p>
<div class="lb-trans"><p>+44 (0) 207 495 2379</p>
</div><p>email: info@tizianalifesciences.com</p>
<div class="lb-trans"><p>電子郵件：info@tizianalifesciences.com</p>
</div><p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
<div class="lb-trans"><p>[1] https://www.pnas.org/doi/10.1073/pnas.2220272120</p>
</div><p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
<div class="lb-trans"><p>[2] https://www.pnas.org/doi/10.1073/pnas.2309221120</p>
</div><p>Photos accompanying this announcement are available at</p>
<div class="lb-trans"><p>本公告附帶的照片可在以下網址獲取</p>
</div><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/48f529f2-1fc4-4466-ae1d-84fa808979a8</p>
<div class="lb-trans"><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/48f529f2-1fc4-4466-ae1d-84fa808979a8</p>
</div><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/bc4d6ed6-2598-489a-859a-f4387ad81ba0</p>
<div class="lb-trans"><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/bc4d6ed6-2598-489a-859a-f4387ad81ba0</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UTTJNQ00zTXpFNU16TTVJekl4TWpNNE9EVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMTM2MCM3MzE5MzM5IzIxMjM4ODU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTc0Yzc3OGEtNzc3OC00OGU1LTkyNjQtNmRhN2FhNjMyM2M4LTExMzU0NTYtMjAyNS0xMi0xMi1lbg==/tiny/Tiziana-Life-Sciences-Plc.png" alt="" original-src="https://ml.globenewswire.com/media/ZTc0Yzc3OGEtNzc3OC00OGU1LTkyNjQtNmRhN2FhNjMyM2M4LTExMzU0NTYtMjAyNS0xMi0xMi1lbg==/tiny/Tiziana-Life-Sciences-Plc.png"/></p>

Tiziana Life Sciences 將在二期阿爾茨海默症試驗中為首位患者用藥 | TLSA 股票新聞